AKYA Stock Overview
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Akoya Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.88 |
| 52 Week High | US$16.57 |
| 52 Week Low | US$7.20 |
| Beta | 0 |
| 1 Month Change | -34.88% |
| 3 Month Change | -22.36% |
| 1 Year Change | -28.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.75% |
Recent News & Updates
Shareholder Returns
| AKYA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -2.0% | -1.7% | -0.3% |
| 1Y | -28.5% | -15.6% | -14.8% |
Return vs Industry: AKYA underperformed the US Life Sciences industry which returned -15.6% over the past year.
Return vs Market: AKYA underperformed the US Market which returned -14.8% over the past year.
Price Volatility
| AKYA volatility | |
|---|---|
| AKYA Average Weekly Movement | 10.1% |
| Life Sciences Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKYA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AKYA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 369 | Brian McKelligon | https://www.akoyabio.com |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services.
Akoya Biosciences, Inc. Fundamentals Summary
| AKYA fundamental statistics | |
|---|---|
| Market Cap | US$294.85m |
| Earnings (TTM) | -US$70.64m |
| Revenue (TTM) | US$74.86m |
4.0x
P/S Ratio-4.3x
P/E RatioIs AKYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKYA income statement (TTM) | |
|---|---|
| Revenue | US$74.86m |
| Cost of Revenue | US$31.47m |
| Gross Profit | US$43.39m |
| Other Expenses | US$114.03m |
| Earnings | -US$70.64m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 57.96% |
| Net Profit Margin | -94.37% |
| Debt/Equity Ratio | 108.0% |
How did AKYA perform over the long term?
See historical performance and comparison